MiR-139 reportedly target Rho-kinase 2 in hepatocellular carcinoma 11, NR5A2 in esophageal cancer 14, NOTCH1 and IGF1R in colorectal cancer 15,28. This evidence concerns the gene ROCK2 and hepatocellular carcinoma.